Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, Japan - Size and Forecast 2024-2028

Vascular Endothelial Growth Factor Inhibitors Market Size 2024-2028

The vascular endothelial growth factor (VEGF) inhibitors market size is forecast to increase by USD 11.67 billion at a CAGR of 8.09% between 2023 and 2028.

• The market is experiencing significant growth due to several key factors. One major driver is the high target affinity and specificity of VEGF inhibitors, making them effective in treating various diseases, including cancer and age-related macular degeneration. Another trend is the increasing popularity of combination therapies, which involve the use of multiple drugs to enhance treatment efficacy and reduce side effects. Additionally, the preference for gene therapy, which offers long-term benefits and precision in treatment, is gaining momentum In the market. These factors are expected to fuel the growth of the market In the coming years.

What will be the Size of the Vascular Endothelial Growth Factor (VEGF) Inhibitors Market During the Forecast Period?

Request Free Sample

• The market encompasses a range of protein therapeutics targeting angiogenesis, the process of new blood vessel formation. These inhibitors play a crucial role in cancer treatment by inhibiting the growth of tumor vessels, thereby limiting the supply of nutrients and oxygen to cancer cells. The market has seen significant growth due to the increasing prevalence of various cancers, including ovarian, cervical, colon and rectum, prostate, breast, lung, and bronchus. Biopharma firms have been actively investing In the development of anti-VEGF therapeutics for various indications, with applications extending to ophthalmic conditions such as macular edema and retinal vein occlusion.
• The market's growth is, however, influenced by factors such as patent cliffs and the emergence of biosimilar drugs, which may impact pricing and market competition. Overall, the VEGF inhibitor market is expected to continue expanding due to the unmet medical need for effective cancer and eye care treatments.

How is this Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry segmented and which is the largest segment?

The industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Application
  • Oncology
  • Ophthalmology
• Type
  • VEGF-A inhibitor
  • VEGF-B inhibitor
  • VEGF-C inhibitor
  • VEGF-D inhibitor
• Geography
  • North America
    • Canada
    • US
  • Europe
    • Germany
    • UK
  • Asia
    • Japan
  • Rest of World (ROW)

By Application Insights

• The oncology segment is estimated to witness significant growth during the forecast period.

VEGF inhibitors play a significant role In the oncology segment due to their approval for various cancer indications, making it the largest market segment in 2023 and expected to maintain its dominance by 2028. The increasing global prevalence of cancers, driven by factors such as gene mutations and lifestyle changes, fuels the growth of this segment. In response, numerous companies are investing in research and development of novel therapeutics, including VEGF inhibitors, to address the substantial unmet need in oncology. Proteins such as VEGF and Hepatocyte growth factor contribute to angiogenesis, and the formation of new blood vessels, which is crucial for tumor growth.

Challenges include side effects like hypertension, stroke, heart attack, impaired wound healing, and patent cliffs, as well as the emergence of biosimilar drugs. Future scope includes applications in ophthalmic conditions like diabetic retinopathy, macular edema, and retinal vein occlusion. Despite these advancements, difficult challenges and threats, such as bleeding and gastrointestinal perforations, remain. Production capacities must be expanded to meet the growing demand in eye care and biopharma applications.

Get a glance at the Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry report of share of various segments Request Free Sample

The Oncology segment was valued at USD 12.52 billion in 2018 and showed a gradual increase during the forecast period.

Regional Analysis

• North America is estimated to contribute 46% to the growth of the global market during the forecast period.

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

The VEGF inhibitor market in North America is driven by the sales of approved drugs for indications such as RCC, melanomas, and NSCLC. According to the National Program of Cancer Registries (NPCR) by the Centers for Disease Control and Protection (CDC), over 28.5 million invasive cancer cases have been diagnosed In the last two decades, with over 1 million new cases reported annually. NSCLC and RCC are among the most common types of cancer in North America, necessitating advanced treatment options. VEGF inhibitors play a significant role in treating various cancers by inhibiting the growth of new blood vessels and angiogenesis.

However, these drugs come with side effects such as hypertension, stroke, heart attack, impaired wound healing, and bleeding. The FDA has approved several VEGF inhibitors, and the entry of biosimilar drugs poses challenges in terms of production capacities and market competition. Future scope lies In the treatment of ophthalmic conditions such as diabetic retinopathy, macular edema, and retinal vein occlusion. The market faces challenges from patent cliffs and the entry of biosimilar drugs, necessitating continuous research and development activities.

Market Dynamics

Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise In the adoption of Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry?

High target affinity and specificity of VEGF inhibitors is the key driver of the market.

• The market encompasses various approved therapies in oncology and ophthalmology, addressing indications such as melanoma, NSCLC, AMD, and RVO. Despite advancements, unmet needs persist due to the prevalence of these conditions and the adverse effects of existing treatments. For instance, chemotherapy, a standard oncology therapy, attacks dividing cells, including cancer cells, but also impacts healthy cells, leading to side effects like hypertension, stroke, heart attack, and impaired wound healing.
• Research activities focus on developing novel therapies as well as addressing challenges such as side effects and patent cliffs. The future scope of the market includes addressing major alterations in tumor growth and expanding product outlook to include indications like leukemia, prostate cancer, breast cancer, lung cancer, bronchus cancer, and pancreatic cancer. However, the market faces difficult challenges, including the development of biosimilar drugs and ensuring production capacities for these therapies. Additionally, the market's future scope includes the treatment of diabetic retinopathy and macular edema.

What are the market trends shaping the Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry?

The growing popularity of combination therapies is the upcoming market trend.

• The market encompasses a significant number of drugs utilized In the treatment of both cancer and ophthalmic conditions. Pharmaceutical research indicates that certain metastatic cancers may not respond to monotherapy drugs, necessitating the use of combination therapies. In these treatments, drugs targeting distinct mechanisms act synergistically at the site, reducing the likelihood of resistant cells developing. Combination therapies have gained traction in cancer treatment and ophthalmology, particularly In the management of conditions such as ovarian, cervical, and various types of cancer, including leukemia, prostate, breast, lung, bronchus, and melanoma. Moreover, VEGF inhibitors are instrumental in treating ophthalmic conditions, such as diabetic retinopathy, macular edema, and retinal vein occlusion.
• Future scope lies in addressing challenges such as the patent cliff and the emergence of biosimilar drugs. Side effects, including hypertension, stroke, heart attack, impaired wound healing, bleeding, and gastrointestinal perforations, necessitate ongoing research activities to improve production capacities and minimize adverse effects. Additionally, VEGF inhibitors play a crucial role in treating eye care conditions, particularly In the context of angiogenesis and tumor growth. Hematologic oncology and neuroscience are other therapeutic areas poised for growth In the VEGF inhibitors market.

What challenges does the Vascular Endothelial Growth Factor (VEGF) Inhibitors Industry face during its growth?

Preference for gene therapy is a key challenge affecting the industry growth.

• Vascular Endothelial Growth Factor (VEGF) inhibitors have gained significant attention In the healthcare industry due to their role in treating various conditions, particularly in oncology and ophthalmology. The pipeline analysis of VEGF inhibitors reveals numerous protein-based therapeutics under development, targeting new blood vessel formation in angiogenesis-related diseases. These conditions include cancer formation in ovarian, cervical, and various solid tumors such as breast, prostate, lung, bronchus, and pancreatic cancer. In immunology and hematologic oncology, these inhibitors are used to target tumor growth and side effects like hypertension, stroke, heart attack, impaired wound healing, and bleeding.
• However, challenges such as gastrointestinal perforations and production capacities limit the market's growth. In ophthalmology, VEGF inhibitors are used for treating diabetic retinopathy, macular edema, and retinal vein occlusion. Gene therapy is a notable area of research activities. Future scope includes the development of biosimilar drugs to reduce costs and expand access to these life-saving treatments. The market faces challenges like patent cliffs and the emergence of biosimilar drugs. Despite these difficulties, the product outlook for VEGF inhibitors remains positive due to their potential to revolutionize the treatment landscape for cancer and ophthalmic conditions.

Exclusive Customer Landscape

The market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.

Customer Landscape

Key Companies & Market Insights

Companies are implementing various strategies, such as strategic alliances, market forecast, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence In the industry.

The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bausch Health Companies Inc.
• Bayer AG
• Bristol Myers Squibb Co.
• Clovis Oncology Inc.
• Eisai Co. Ltd.
• Eli Lilly and Co.
• Exelixis Inc.
• F. Hoffmann La Roche Ltd.
• LG Chem Ltd.
• Merck and Co. Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd.
• Viatris Inc.
• Xbrane Biopharma AB

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Research Analyst Overview

Vascular Endothelial Growth Factor (VEGF) inhibitors represent a significant class of therapeutics In the biopharmaceutical industry, with a focus on modulating the angiogenic process, a critical factor in various pathological conditions, including cancer formation and ophthalmic diseases. These proteins play a pivotal role In the development of new blood vessels, a process essential for tumor growth and progression. The pipeline of VEGF inhibitors is diverse, with numerous oncology candidates under development. Similarly, Osimertinib, a tyrosine kinase inhibitor, targets the Hepatocyte Growth Factor (HGF) pathway, which interacts with the VEGF signaling cascade.

VEGF inhibitors have shown promising results in various cancer types, including ovarian, cervical, leukemia, prostate, breast, lung, bronchus, melanoma, and pancreatic cancer. In hematologic oncology, these agents have demonstrated efficacy in managing tumor growth and improving patient outcomes. Immunology is another therapeutic area where VEGF inhibitors have gained attention. These agents can enhance the immune response against tumors by inhibiting the formation of new blood vessels, thereby limiting the tumor's ability to grow and spread. Despite the significant progress, the market for VEGF inhibitors faces notable challenges. Major alterations In the competitive landscape, such as the emergence of biosimilar, may impact the market dynamics. Additionally, gastrointestinal perforations and production capacities are other challenges that manufacturers must address to ensure the safe and efficient delivery of these therapies.

Request Free Sample

What are the Key Data Covered in this Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Research and Growth Report?

• CAGR of the industry during the forecast period
• Detailed information on factors that will drive the market growth and forecasting between 2024 and 2028
• Precise estimation of the size of the market and its contribution to the industry in focus on the parent market
• Accurate predictions about upcoming growth and trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market's competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the market growth of industry companies

We can help! Our analysts can customize this market research report to meet your requirements.

Get in touch